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CytoarchitectureThe heart is responsible for pumping blood throughout the blood vessels to the periphery by repeated, rhythmic
contractions at variable intensity. As such the heart should permanently adjust energy production to energy
utilization and is a high-energy consumer. For this the heart mainly depends on oxidative metabolism for
adequate energy production and on efﬁcient energy transfer systems. In heart failure, there is disequilibrium
between the work the heart has to perform and the energy it is able to produce to fulﬁll its needs. This has led to
the concept of energy starvation of the failing heart. This includes decreased oxygen and substrate supply, altered
substrate utilization, decreased energy production by mitochondria and glycolysis, altered energy transfer and
inefﬁcient energy utilization. Mitochondrial biogenesis and its transcription cascade are down-regulated.
Disorganization of the cytoarchitecture of the failing cardiomyocyte also participates in energy wastage. Finally,
the failing of the cardiac pump, by decreasing oxygen and substrate supply, leads to a systemic energy starvation.
Metabolic therapy has thus emerged as an original and promising approach in the treatment heart failure. This
article is part of a Special Issue entitled: Mitochondria and Cardioprotection.e; AK, adenylate kinase; ADP,
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The heart is among the largest energy consumer organ in the body.
Energy is stored in the form of ATP and phosphocreatine (PCr) which
is formed by the phosphorylation of creatine from ATP by creatine
kinase (CK). The heart consumes around 1 mMATP/s. This means that
all ATP and PCr content should be renewed every ≈20 s. Because
heart muscle produces more than 90% of its energy from mitochon-
drial respiration, it is a highly oxidative tissue. As a consequence, there
is a strict correlation between cardiac oxygen consumption and
cardiac work showing that the bioenergetic of the heart is of the tight
ﬂux mode (Fig. 1).Among cardiac pathologies, heart failure has increasing prevalence
in industrialized countries. Heart failure (HF) is a clinical syndrome
that is characterized by progressive deterioration of the pump
function leading to the incapacity of the heart to meet the body
requirements. Heart failure patients also suffer from decreased
exercise capacity increased fatigability, as well as dyspnea. Decreased
fatigue resistance is intricately linked to energetic failure of the
skeletal and respiratory muscles.
Heart failure originates from a mismatch between the demand of the
organism and the capacity of the heart to fulﬁll its pump function. This
mismatch may result from decreased oxygen and substrate delivery
caused by chronic hypoxia, atherosclerosis, coronary artery disease, or
mitochondrial defects induced by genetic or toxic factors. It may also
result from increased workload to the myocardium following hyperten-
sion, for example, or from altered cardiac structure, or inefﬁcient ATP
utilization leading to decreased efﬁciency of energy utilization. As a
consequence of the pump failure, oxygen and substrates are not
adequately delivered to the periphery and metabolic products are not
effectively cleanedupcreatinga stateof energydeﬁciency in theorganism
and for theheart itself.Oneof the consequencesof cardiac failure is thus to
decrease oxygen and substrates availability for the organism.
Chronic stress to the myocardium initiates an adaptive process
that comprises left ventricular hypertrophy, and functional and
metabolic remodeling. However, when the stress exceeds the
adaptive capacity or is prolonged, it can be followed by excessive
maladaptive hypertrophy, progressive ventricular dilatation, contrac-
tile dysfunction, and, ultimately, heart failure. Progression to failure
involves neuroendocrine overdrive, activation of intracellular
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Fig. 1. Relationship between cardiac work and oxygen consumption in normal and
failing rat hearts. RPP, rate pressure product, QO2, oxygen consumption (drawn from De
Sousa et al. [15]).
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Many of these contributing factors induce increased energy demand
and thus a progressive imbalance between energy supply and
demand. This leads to energy starvation that has been postulated as
a central and potentially important factor contributing to heart failure
development [1–6]. Energy starvation is manifest at different levels of
cardiac energy metabolism. It could be taken as a unifying mechanism
leading to cardiac contractile failure, and ultimately resulting in
skeletal muscle energetic failure, exercise fatigue and death [6].
2. Substrates utilization
The heart is generally considered as a substrate omnivore with the
capacity to oxidize fatty acids, carbohydrates, ketone bodies, lactate
and even amino acids, the preferred substrate being fatty acids.
Metabolic ﬂexibility of the heart is its ability to respond to changing
workload, substrate availability, circulating hormones, coronary ﬂow,
fuel metabolism by choosing the right substrate at the right moment
(see [7,8] for reviews).
Studies of substrate utilization in the normal and failing heart have
yielded conﬂicting results and interpretations and is the subject of
recent extensive reviews elsewhere [8,9] and in this special issue of
the journal and will be brieﬂy summarized here.
It is generally reported that very early during the adaptive phase of
hypertrophy, themyocardial energy source switches from fatty acid to
glucose oxidation. However, metabolic adaptation may depend more
on the nature of the stimulus inducing hypertrophy than on
hypertrophy itself. These stimuli could be of physiological (exercise
training, pregnancy) or pathological (hypertension) origin. Although
exercise training increases mitochondrial fatty acid oxidation capac-
ity, and hypertension decreases it, neither pregnancy or later stages of
hypertension signiﬁcantly affected it, showing that there is no unique
metabolic signature in the hypertrophied heart [10].
In human heart, in the early stages of HF there is a normal (or slightly
elevated) rate of fatty acid utilization, with a dramatic downregulation of
fatty acid oxidation in advanced or end-stage HF [8]. Downregulation of
fatty acid oxidation (FAO) pathway is linked to a metabolic remodeling
involving downregulation of the PPARα/RXRα pathway [9,11–13] (see
below). An increase in glycolysis and in glycolytic enzymes can be
observed in hypertrophy but rapidly, rates of glucose oxidation are
reduced as well as expression of proteins and transporters of glycolysis
and carbohydrate oxidation [11,13–17]. As the process of remodeling
progresses towards uncompensated state,metabolic adaptation becomes
insufﬁcient with a lower capacity to oxidize glucose leading to decreased
efﬁciency [18] and loss of metabolic ﬂexibility [19].There is thus evidence that impaired substrate metabolism
contributes to contractile dysfunction and cardiac remodeling
characteristic of heart failure.
3. Mitochondrial capacity and function
3.1. Regulation of mitochondrial function in normal heart
Mitochondria occupymore than 30% of the cardiomyocyte volume.
They are densely packed, organized under the sarcolemma and in
rows between myoﬁlaments such that a constant diffusion distance
exists between mitochondria and the core of myoﬁlaments. This type
of organization provides a bioenergetic basis for contraction com-
prising cytoskeletal protein, mitochondria and sarcoplasmic reticu-
lum at the level of a sarcomere within Intracellular Energetic Units
[20].
During high-intensity exercise, the heart uses more than 90% of its
maximal oxidative capacity [21], showing that there is no excess
capacity of energy production over energy utilization. The strict linear
relationship between oxygen consumption and cardiac work occurs at
constant global cellular ATP and phosphocreatine (PCr) concentra-
tions. This signs the peculiarity of the heart that is to work at
metabolic homeostasis, expressed as constancy in concentrations of
ATP, PCr and creatine, despite large variations inworkload and oxygen
consumption, or vice et versa [22,23]. Small metabolite oscillations
during the cardiac cycle that may contribute to feedback metabolic
regulation of respiration on a beat-to-beat basis, have been observed
experimentally [24] and described by mathematical modeling [25].
The need for global metabolic homeostasis during changing energy
demands imposes a major constraint on all cells. The mechanisms
underlying this homeostasis are still highly debated, and few studies
have carefully addressed the problem [22,25,37].
Therefore, strong energy signaling pathways should exist to
ensure the close match between oxygen consumption and energy
utilization. At present, the nature and function of such signals are still
under debate and oxygen and substrates supply, ATP, ADP, PCr and Pi
changes, calcium, redox state, phosphotransfer systems have all been
considered to play a role. Their relative contribution to energy
metabolism homeostasis if any will depend on the mechanical load
and the metabolic conditions the heart has to respond to. Among
these factors, two of them have been extensively considered. One of
the candidates for coupling aerobic metabolism and cardiac work is
calcium as it regulates myosin and sarcoplasmic reticulum ATPases on
one hand, and the major mitochondrial dehydrogenases and F0/F1
ATPase on the other [26–28]. However, the assumption that
respiration and contraction are simultaneously regulated by Ca2+-
ions is not completely satisfactory, as parallel increase in cardiac work
and oxygen consumption with increase in length (Frank-Starling
mechanism) occurs at constant intracellular Ca2+ concentration
[22,29].
Another mechanism of regulation relies on the existence of
energetic microdomains at sites of energy production and utilization,
where the concentrations of ATP and ADP can be different from the
rest of the cell. These microdomains are interconnected by phospho-
transfer kinases and cell architecture. Indeed, the cardiomyocyte is
not a well-mixed bag [30] and the reactions involved in ATP
generation and utilization are not governed by stochastic events,
but are rather integrated within structural and functional entities,
spatially and temporarily coordinated. Glycolytic enzymes are
arranged in supramolecular complexes bound to intracellular struc-
tures such as myoﬁlaments and sarcoplasmic reticulum, where they
participate in local energy production, more readily used by ion
pumps and other membrane structures [31]. Mitochondria are
embedded in the cytoskeleton in close interaction with surrounding
organelles like sarcoplasmic reticulum, myoﬁlaments and nucleus.
This supramolecular arrangement induces speciﬁc regulatory
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far lower than in isolated mitochondria [32,33]. Low sensitivity to
bulk ADP allows adenine nucleotide channeling and ﬁne control of
oxygen consumption by ATPases. The restricted access of cytosolic
ADP to the mitochondrial compartment is possibly due to interaction
of mitochondria with cytoskeletal proteins and molecular crowding
[34]. Indeed, recently, tubulin has been shown to interact with porin
and to decrease the permeability of porin and regulate respiration
[35]. Disruption of the cytoskeleton increases the sensitivity to ADP
and blunts the ﬁne control of mitochondrial respiration [36]. The
system of compartmentalized creatine kinase isoenzymes (see below)
coupled to adenine nucleotide translocase (ANT) or ATPases allows
the interconnection between ATP production and utilization due to
the non-equilibrium state of the CK reaction. The mechanisms
underlying the feedback regulation of respiration and energy ﬂuxes
are now analyzed on the framework of systems biology and includes
small cyclic ﬂuctuations of cytosolic metabolites [25]. The readers
should refer to the excellent reviews by V. Saks and his coworkers for
more comprehensive analysis of regulation of energy ﬂuxes in muscle
cells [22,25,37].
3.2. Mitochondrial function in heart failure
One important determinant of the capacity to oxidize different
substrates is the oxidative capacity of the failing heart. In failing
myocardium, it is unclear whether peak O2 utilization is limited by
maximal oxidative ATP synthetic capacity or by the maximal
capacities of the ATPases to utilize ATP. Inadequate intracellular
oxygen availability does not seem to be a limiting factor of oxygen
consumption [38]. On the other hand, at high workloads, O2
consumption rate by the failing myocardium can reach a maximum
and becomes limited [38]. The maximal capacity to utilize oxygen is
determined by the mass of mitochondria and by their intrinsic
activity. Maximal oxidative capacity of the heart can be estimated by
measuring the activity of key enzymes like citrate synthase, or
cytochrome oxidase. In human and experimental HF, decreases in the
activity of complexes of the respiratory chain or Krebs cycle enzymes
or F(0)F(1)-ATPase protein expression have been largely reported
[15,16,39–44] that correlate with cardiac function [45]. In addition,
large scale proteomic and transcriptomic studies have conﬁrmed that
alteration in energy production and mitochondrial dysfunction is
involved in the development of heart failure [46–48]. Of uppermost
interest is the observation that the genomic HF proﬁle observed in a
model of pacing-induced heart failure in dogs is characterized by
predominant downregulation of metabolic processes as early as
3 days after the initiation of rapid ventricular pacing evidencing that
metabolic alteration is an early event in the pathophysiology of heart
failure [49,50]. Thus not only alterations of metabolic processes are
central in heart failure but they also represent early events in the
pathophysiological process.
Moreover, mitochondria can also exhibit changes in properties.
Decreased ADP/O ratio has been observed that is reﬂected in a 14%
decrease in efﬁciency of the failing hearts [51]. A role for the
supramolecular assembly rather than for the individual components
of the electron transport chain has also been proposed [52]. Moreover,
alterations in transport capacity of the ANT, and changes in isoform
expression was observed in CHF patients [39,53]. In addition, an
increased susceptibility of mitochondria to calcium and reactive
oxygen species has been described in failing hearts. Themitochondrial
permeability transition deﬁnes a sudden increase in the permeability
of the innermitochondrial membrane that is attributed to the opening
of a high-conductance channel that is termed permeability transition
pore (PTP) [54]. Increased susceptibility of the PTP to calcium and
reactive oxygen species is involved in apoptosis and necrosis of the
cardiomyocyte. However, some data argue for an early increase in PTP
susceptibility in hypertrophy and heart failure [55,56]. These changesoccur before any changes in mitochondrial respiration properties,
evidencing a stage of preclinical mitochondrial dysfunction.
Isolated mitochondria allow assessment of the speciﬁc activity of
mitochondria but not of the overall oxidative capacity of the tissue. The
low yield of cardiac mitochondria isolation, the selection bias during
isolation and the changes in mitochondrial regulation limit the
extrapolation of isolated mitochondria studies to the living heart. More
directly, oxidative capacity can be approached by recording maximal
oxygen consumption rate normalized to dry weight in permeabilized
cardiac ﬁbers. A general decrease in oxidative capacity has been reported
in different models of heart failure [15,57–62] as well as in humans
[59,63]. This decrease in oxidative capacity was evident for all substrates
but was larger with fatty acids (Rimbaud et al. unpublished data). This
shows that in heart failure, fatty acid oxidation is impaired by two
mechanisms, a decrease in mitochondrial activity and in addition a
speciﬁc decrease in mitochondrial fatty acid oxidation capacity.
In addition to an overall decrease in the capacity to utilize oxygen,
the failing heart exhibits alterations in the regulation of respiration by
the phosphate acceptors AMP, ADP and creatine [15,57–59]. Interest-
ingly the decreased sensitivity to ADP is accompanied by cytoskeleton
remodeling and increased content of tubulin [64,65] although the cause
andeffect relationshipneeds tobe established. Thedecreased sensitivity
to creatine is explained by the decreased expression and content of
mitochondrial creatine kinase which largely exceeds the decrease in
oxidative capacity [15]. A similar defect in coupling betweenmitochon-
drial respiration andmyokinase could be shown [15]. This is responsible
for a lower and less efﬁcientmyocardial energy production via oxidative
phosphorylation in HF. Decreased oxidative capacity on one hand and
blunted servoing ofmitochondria to excitation–contraction coupling on
the other, will precipitate the heart in starvation.
Due to the strict correlation between oxygen consumption and
work, the decreased oxidative capacity of the failing myocardium and
the loss of functional coupling with sites of energy utilization will
limit work and participate in cardiac dysfunction.
4. Mitochondrial biogenesis
Decreased oxidative capacity of the failing myocardium can arise
from an unbalance between mitochondrial biogenesis and degrada-
tion. In the recent years, mitochondrial biogenesis has emerged as an
important point among the multi-site control of mitochondria [66].
Mitochondrial biogenesis can be deﬁned as the processes and
events resulting from the growth and division of pre-existing
organelles. It includes mitochondrial protein expression and its
molecular control, phospholipids synthesis, import of mitochondrial
proteins and mitochondrial network dynamics. Due to their ancient
bacterial origin, mitochondria possess their own genome which
encodes for 13 proteins whereas more than 98% of the mitochondrial
protein requirement is encoded by the nuclear genome. Hence, to
ensure a proper mitochondrial biogenesis, this requires a spatiotem-
poral coordination between protein synthesis, nuclear-encoded
protein import and assembly with mitochondrial-encoded proteins.
In addition, mitochondrial DNA replication and mitochondrial fusion
and ﬁssion mechanisms must also be coordinated [67]. Thus, a defect
in these multiple processes that constitute mitochondrial biogenesis
could lead to impaired mitochondrial function and contribute to
cardiac contractile failure. The discovery that alterations in mito-
chondrial biogenesis contribute to cardiac pathologies such as
hypertrophy or failure have increased the interest of the scientiﬁc
community in this process and its regulation.
4.1. Molecular control of mitochondrial protein expression
4.1.1. Mitochondrial biogenesis in the normal heart
Metabolic control of mitochondrial biogenesis will be developed
elsewhere in this issue. This chapter will thus brieﬂy review the
Fig. 2. PGC1α regulatory cascade. PGC-1α co-activates transcription factors such as nuclear respiratory factors (NRFs), estrogen-related-receptors (ERRs) and PPARs, known to
regulate different aspects of energy metabolism including mitochondrial biogenesis, fatty acid oxidation and antioxidant.
Fig. 3. Transcriptional cascade of mitochondrial biogenesis. Gene expression levels of
PPARγ coactivator-1α (PGC-1α), PPARγ coactivator-1β (PGC-1β), and PGC-1 related
coactivator (PRC) in left ventricle (LV), oxidative soleus muscle (SOL) and glycolytic
part of gastrocnemius muscle (GAS) of sham-operated (SHAM) rats (A) and rats with
chronic heart failure (HF) induced by aortic banding [85] (B). mRNA expression was
measured by real-time RT-PCR according to [85], and were normalized to ribosomal
protein A and TATA box binding protein levels using GeNorm software. Results are
given as means±SEM, *pb0.05, **pb0.01 and ***pb0.001 versus SHAM-LV group (A)
or respective SHAM group (B).
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focus on the alterations that occur during heart failure.
The tuning of the mitochondrial protein expression is largely
achieved at the level of transcriptional regulation. It depends on a
highly interconnected network between coregulators and various DNA-
binding transcription factors that regulate a broad set of nuclear genes
encodingmitochondrial proteinshaving a functional or a regulatory role
for the mitochondria (Fig. 2). The transcriptional coactivator peroxi-
some proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a
master regulator of energymetabolismat the level of gene transcription.
Through its interaction with multiple transcription factors such as
peroxisome proliferator-activated receptors (PPARs), estrogen receptor
related receptor (ERRs) or nuclear respiratory factor (NRFs), PGC-1α
enhances mitochondrial capacity for fatty acid oxidation and oxidative
phosphorylation and triggers the coordinate expression of nuclear and
mitochondrial-encoded genes driving mitochondrial biogenesis [67–
70]. Indeed, PGC-1α also activates the transcription and replication of
mitochondrial DNA by transcriptionally activating and co-activating
NRFs, which activate the transcription of the nuclear-encoded mito-
chondrial transcription factor A (TFAM), and of two proteins that
interact with the mammalian mitochondrial RNA polymerase and
TFAM, TFB1M and TFB2M (for review see [67,71,72]).
PGC-1α activates other nuclear receptors and transcription factors
that are involved in mitochondrial biogenesis (Fig. 2). The principal
transcriptional regulators of FAO enzyme genes are PPARα and δ,
members of the ligand-activated nuclear receptor superfamily.
Activation of PPARα by long-chain fatty induces a transcriptional
response leading to increased expression of FAO enzymes [73]. PPARδ
is an essential transcriptional regulator for mitochondrial protection
and biogenesis in adult heart [74]. ERRα upregulates a subset of PGC-
1alpha target genes involved inmultiple energy production pathways,
including cellular fatty acid transport, mitochondrial and peroxisomal
fatty acid oxidation, and mitochondrial respiration [75].
PGC-1α belongs to a small family of coactivators including PGC-1β
and PGC-1 related coactivator (PRC) [71]. As depicted in Fig. 3, only
PGC-1α and PGC-1β gene expression strictly follows the muscle
mitochondrial oxidative capacity, suggesting an important role of
these two coactivators in setting the tissue-speciﬁc oxidative capacity.
PRC gene expression is considerably lower than the expression of
PGC-1α and PGC-1β in healthy muscles and does not seem to be
expressed in a tissue-speciﬁc manner. Studies of loss of function
leading to a defect of PGC-1α or PGC-1β in mice showed no profound
alterations in basal cardiac phenotype, suggesting that these two
coactivators partly compensate for each other's loss in vivo (see
references in [72]). The recent generation of double PGC-1α/PGC-1βnull mice has conﬁrmed this notion as these mice die shortly after
birth as a result of heart failure related to an arrest in cardiac
maturation including a block inmitochondrial biogenesis [76], despite
the presence of PRC.
Additionally, mitochondrial biogenesis involves fusion/ﬁssion and
requires protein import and processing and cardiolipin biosynthesis.
Mitochondrial shape is determined by ﬁssion and fusion of mito-
chondrial membranes, mediated by proteins bearing a GTPase activity
in their N-terminal domain. Fission involves the dynamin-related
protein 1 (Drp1) and its receptor Fis1 while fusion is mediated by two
dynamin-related proteins, mitofusin (Mfn1 and 2) involved in outer
membrane fusion, and OPA1 (Optic atrophic type 1 protein) that is
closely related to the inner membrane (for reviews see [77,78] and
dedicated chapter in this issue). Mitochondrial fusion and ﬁssion are
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mitochondrial network disorganization and dysfunction.
Mitochondrial dynamics has been well described for differentiat-
ing and cancer cells, but such fast fusion/ﬁssion mechanisms do not
seem to occur in adult cardiomyocytes [79]. Fusion and ﬁssion
proteins are highly expressed in the heart and it is not excluded that
this phenomenon could be involved in much slower processes and for
example plays an important role during mitochondrial biogenesis
during cardiac growth and postnatal cell maturation. It may also
intervene in response to stress like ischemia, hypertrophy and heart
failure [80–82]. This emerging ﬁeld needs further investigation in
mature cardiac cells.
Whether the transcriptional regulation of these processes involves
the same or similar transcription cascades is still largely unknown.
However, in skeletal muscle, PGC-1α and mitochondrial content
correlate strongly with expression of proteins involved in mitochon-
drial dynamics and protein processing [83]. Moreover, evidence for a
mitochondrial regulatory pathway deﬁned by PGC-1α/ERRα and
mitofusin 2 has been described [84] suggesting that partners of
mitochondrial dynamic could also be regulated by PGC-1α.
4.1.2. Mitochondrial biogenesis in heart failure
Addressing the origin of decreased cardiac muscle oxidative
capacity in the pathogenesis of heart failure, we previously showed
in a ratmodel of CHF induced by pressure overload that the decrease in
mitochondrial function in both cardiac and skeletal muscles is linked
to altered expression of mitochondrial proteins associated with
decreased expression of PGC-1α, and its downstream transcription
factors NRFs and TFAM [85]. Decreased cardiac PGC-1α was subse-
quently described in numerous models of heart failure [86–90],
strongly suggesting that downregulation of this PGC-1α transcrip-
tional cascade is a real metabolic signature of heart failure, leading to
reduced mitochondrial protein expression encoded either by nuclear
or mitochondrial genome and defective oxidative capacity [67].
Recent studies have examined the PGC-1α transcriptional cascade
in human heart failure and the results are quite controversial and
suggest that PGC-1α downregulation is not uniformly present in
human failing hearts [63,91–93]. This discrepancy between animal
models and human diseases could be linked to the nature and/or the
severity of the disease, the lack of age-matched control group, the sex
differences between groups, and the treatment used for patients.
Nevertheless, decreased expression of the key PGC-1α regulatory
partner ERRα, as well as ERRα target genes will participate in the
downregulation of mitochondrial metabolic capacity in human failing
heart [92].
Only few studies have explored expression of PGC-1β in heart
failure. A decrease in PGC-1β was reported in human dilated
cardiomyopathy but not in ischemic heart disease [91]. We explored
the gene expression of PGC-1β, PRC and ERRα in our rat model of
heart failure induced by aortic banding. As for PGC-1α and NRFs [85]
we observed a signiﬁcant decrease in PGC-1β and ERRα expression in
HF (Fig. 3). Thus, this concomitant downregulation of PGC-1α and
PGC-1β gene expression in the failing myocardium reinforce the
importance of the mitochondrial biogenesis defect in this pathology.
In an opposite way, although expressed at a much lower level, PRC
gene expression is increased in failing rat hearts but its precise
biological function in mitochondrial biogenesis awaits further
characterization. As ERRα is required for the adaptive bioenergetic
response to hemodynamic stressors known to cause heart failure [94],
the decreased expression of ERRα may participate in the energetic
failure of the myocardium. To conclude, heart failure is characterized
by an overall downregulation of energy metabolism involving the
PGCs/PPARs/ERRs axis.
At present the transcriptional control of the CK system is poorly
understood. In muscle cells, M-CK activity is inversely related to the
mitochondrial content, while mi-CK activity increases with oxidativecapacities [95]. To our knowledge, whether the expression of the
mitochondrial protein mi-CK could be controlled by the classical
mitochondrial biogenesis transcription cascade has not been exten-
sively studied. However, downregulation of mi-CK have been
observed in skeletal muscle [96] and heart [97] of PGC-1α KO mice
suggesting that it is indeed the case. Moreover, mi-CK appears to be
regulated by both ERRα and γ [98].
Nevertheless, all these results converge to an impairment of
mitochondrial biogenesis in failing heart through a deactivation of the
PGC-1α transcriptional cascade and a reduced mtDNA replication and
depletion.
4.2. Qualitative and quantitative defects in mtDNA
The decline in mtDNA-encoded proteins observed in failing hearts
could be also attributable to qualitative and/or quantitative defects in
mtDNA content. However, results obtained either in experimental
heart failure or in human heart failure are still under debate. A
decrease in mtDNA copy number was described in a murine model of
myocardial infarction [99], although our results did not reveal a
signiﬁcant difference in the mtDNA content between healthy and HF
cardiac muscles of rats [85]. Several studies have reported maintained
mtDNA content in patients with idiopathic dilated or ischemic
cardiomyopathy [11,44,91,100]. A recent report from the group of R.
Tian evidenced an impairment of mitochondrial biogenesis in human
heart failure via a reducedmtDNA replication and depletion of mtDNA
in the human failing heart [93].
Recent experimental and clinical studies have suggested that
oxidative stress is enhanced in heart failure. This chronic increase in
oxygen radical production in the mitochondria can induce mitochon-
drial DNA damage, which leads to defects of mtDNA-encoded gene
expression, dysfunction of the respiratory chain complexes and thus
may contribute to the progression of heart failure [99,101,102]. This
mtDNA damage as well as left ventricular remodeling and failure after
MI could be prevented by mitochondria-targeted antioxidants [103].
TFAM is essential for mtDNA transcription and replication and a
decrease in its expression is observed in cardiac failure. Studies of loss
or gain of function demonstrate that TFAM can function as a limiting
determinant of mtDNA copy number and that copy number control by
TFAM is independent of its transcriptional function [71]. In addition, it
was shown by varying mtDNA amounts that oxidative phosphoryla-
tion activities are tightly controlled by the amount of mtDNA in the
cell [104]. Interestingly, an overexpression of TFAM could ameliorate
the decline in mtDNA copy number in failing hearts, mitochondrial
deﬁciencies and cardiac failure after myocardial infarction [105,106].
In addition, a defect in the replication mechanism of the mtDNA could
impair mitochondrial biogenesis and function in human failing hearts
[93]. Thus, depletion of the mitochondrial DNA copy number could
also be an important “actor” to the mitochondrial defects underlying
human heart failure.
4.3. Import of mitochondrial protein
The targeting, import and assembly of nuclear-encoded mitochon-
drial proteins are essential processes of mitochondrial biogenesis.
They involve a complex series of events which are dependent on the
information encoded in the imported protein, the mitochondrial
translocation machinery and the chaperones involved in the proper
folding and assembly of proteins once they are imported (for review
see [107,108]). It has been shown that errors in these events either by
protein mutation or deﬁciency can result in a protein not reaching its
ﬁnal destination, ultimately leading to a disease state in humans often
associated with characteristic features of cardiac myopathy and
neurodegeneration (for review see [109]). A decrease in inner
mitochondrial membrane proteins including mitochondrial protein
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[110] but data are lacking in heart failure.
4.4. Mitochondrial phospholipid synthesis
Mitochondrial biogenesis also involves the proliferation of mito-
chondrial membranes. Phospholipids are important structural and
functional components of mitochondrial membranes [111], and are
implicated in the regulation of various processes including apoptosis,
electron transport, and mitochondrial lipid and protein import.
Cardiolipin is a unique phospholipid which is almost exclusively
located in the inner mitochondrial membrane where it is biosynthe-
sized. This phospholipid is known to play a key role in the activity of
several inner membrane proteins and in the binding of mitochondrial
creatine kinase in the vicinity of translocase. Defects in cardiolipin
structure, content and acyl chain composition have been associated
with mitochondrial dysfunction in multiple tissues in several
physiopathological conditions including heart failure (for review
[112,113]).
The mechanism(s) of alterations in cardiolipin biosynthesis and/or
remodeling in the failing heart are not well known. Prior studies have
argued against a role of chronic adrenergic stimulation whereas a role
for mitochondrial calcium-independent phospholipase A(2) has been
proposed (reviewed in [112]). Thyroid hormones and AMPKα2 are
also involved in the control of mitochondrial respiration through
cardiolipin homeostasis [111,114]. Further studies are needed to
identify the mechanisms involved in the regulation of mitochondrial
phospholipids synthesis in heart failure.
4.5. Turnover of mitochondria, and mitophagy
Mitochondria possess excellent protein quality-control systems.
The only way which provides a mechanism for selective removal of
deterioratingmitochondria is mitochondrial autophagy or mitophagy.
The mitochondrial quality-control hypothesis was ﬁrst advanced by
the Shirihai's group [115]. They propose a mechanism by which the
integration of mitochondrial fusion, ﬁssion and autophagy forms a
quality maintenance system. Mitochondrial fusion and ﬁssion are
paired, fusion triggers ﬁssion, allowing a redistribution of damaged
mitochondrial components into daughter mitochondria that is
targeted for autophagic destruction. So, the deregulation in mito-
chondrial network dynamics and morphology in failing myocardium,
could thus lead to alteration in mitophagy and to dysfunctional
mitochondria, but this remains to be explored.
5. Energy reserves
PCr/ATP ratio, which can be followed owing to the development of
31P Nuclear Magnetic Resonance (NMR) on the whole heart in vivo, is
considered as a powerful index of the energetic state of the heart.
Depending on the species, the PCr/ATP ranges from 1.7 to 2.1. It
reﬂects both the mitochondrial ATP production and the efﬁcacy of
energy transfer by creatine kinase. The failing heart is unable to
maintain its energetic reserve. Alterations in myocardial high-energy
phosphates were identiﬁed in animal models and human hearts with
left ventricular hypertrophy or heart failure. A decrease in PCr/ATP
ratio and an increase in calculated ADP is consistently reported in
animal models of pressure overload and heart failure [38,43,116–120]
and in hypertrophied and failing human hearts [121–127] (for recent
reviews see [4,128]). PCr decrease is mainly responsible for this
observation since its concentration is decreased from 50 to 70% in the
early stages, whereas [ATP] is almost preserved [124,127] or slightly
diminished by at most 30% [117,126]. Interestingly, in studies where
left ventricular hypertrophy and HF are compared, the PCr/ATP ratio
already drops during the phase of severe hypertrophy and before HF
[118,119,127]. A loss of total creatine content and of purines is alsoobserved and is considered adaptive as it allows to preserve the free
energy of ATP hydrolysis [128,129]. Importantly, PCr/ATP ratio
correlates with hemodynamic factors [130] and is of predictive
value in heart failure [131]. Moreover, compromised energetics is also
evident in hypertrophic cardiomyopathy [128,132] suggesting a
central role for altered energetics in cardiac hypertrophy and failure
[133]. The precise cellular mechanisms linking compromised high-
energy phosphate levels and contractility are not well understood.
However, for the reasons discussed above, the decrease in PCr/ATP
ratio is more a reﬂection of altered energy ﬂuxes rather than a cause.
Certainly of major importance, PCr/ATP decline is accompanied by a
local increase in ADP concentration that will affect both thermody-
namically and kinetically the ATPases involved in excitation–
contraction coupling [15,134].6. Energy phosphotransfer
6.1. Energy phosphotransfer in normal heart
The presence of high-energy phosphotransfer systems is another
essential feature of striated muscle energy metabolism. Early in the
seventies, Bessman identiﬁed the creatine kinase (CK) and adenylate
kinase (AK) systems as energy shuttles [135]. Since that time,
considerable pieces of evidence have been accumulating to under-
stand high-energy transfer in cardiac and muscle cells. Muscle cells
use phosphotransfer networks, consisting of multiple near-equilibri-
um enzyme reactions, to convey energy-rich phosphoryl groups
between cellular compartments in a kinetically and thermodynam-
ically efﬁcient manner [34,136,137]. Most phosphoryl groups are
transferred between sites of ATP production and consumption via
multiple creatine kinase catalyzed phosphoryl exchanges.
CK is present in variable amounts in heart and skeletal muscles and
catalyses the reversible transfer of a phosphate moiety between ATP
and creatine. Four different isoforms have been described and are
expressed in a tissue-speciﬁc and developmentally regulated manner.
Cytosolic CK exists as dimers composed of two subunits, M and B,
giving three isoenzymes, MM, BB, and MB. A fourth isoenzyme
speciﬁcally found in the mitochondria (mi-CK), can form both
octameric and dimeric structures [138] and represents 20 to 40% of
all CK activity in cardiac cells. CK isoenzymes are not evenly
distributed and the CK system constitutes an example of a
compartmentalized metabolic pathway. Myoﬁbrillar MM-CK is a
structural protein of the myoﬁlaments and is functionally coupled to
the myosin ATPase, thus providing enough energy to sustain maximal
force and normal kinetics of contraction [139,140]. MM-CK is also
strongly bound to the sarcoplasmic reticulum (SR) membranes where
it is functionally coupled to the Ca2+-ATPase (SERCA), and ensures
efﬁcient energy provision for calcium uptake [95,141,142]. Another
local functional coupling takes place in the intermembrane space of
mitochondria, where mi-CK is found on the outer surface of the inner
mitochondrial membrane, in the vicinity of the ANT. During active
oxidative phosphorylation, ATP generated in thematrix is exported by
ANT in the intermembrane space where it is trans-phosphorylated by
mi-CK to PCr and ADP in the presence of creatine. ADP is then
immediately available for oxidative phosphorylation and further
stimulates respiration (for reviews and further references see
[34,37,136,138]. Cardiac mitochondrial respiration is mainly con-
trolled by creatine due to the tight coupling between mitochondrial
creatine kinase and ANT in the intermembrane space and to the low
sensitivity of respiration for bulk ADP. Addition of creatine thus
lowers the apparent Km for ADP (for a recent review see [37]). This
allows the ﬁne coupling between energy utilization by cytosolic
ATPases and mitochondrial respiration. The same is true for
mitochondrial myokinase also present in the inner membrane space
of mitochondria [143].
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consuming sites and CK, efﬁciently control local ATP/ADP ratios that
thermodynamically and kinetically favor energy production in
mitochondria (low ATP/ADP ratio) and energy consumption in
cytosolic compartments (high ATP/ADP ratios). These sites are
connected through the near-equilibrium CK reactions that take
place in the cytosol, and result in almost instantaneous transfer of
phosphoryl groups to ATPases and of metabolic signal to mitochon-
dria. Quantiﬁcation of 31P NMR unidirectional ﬂuxes of localized CKs
[144] and mathematical modeling [145–147] provided strong evi-
dence for the existence of localized adenine nucleotide pools
interrelated through intracellular energy transfer by CK. Indeed,
creatine kinase ﬂuxes are compartmentalized in intact cells, and the
distribution of ADP has to be heterogeneous for the system to work,
thus emphasizing the importance of subcellular organization and
compartmentation in energy transfer [146,148,149]. Among phos-
photransfer kinases, CK system appears the most important, but
others phosphotransfer systems such as myokinase are also present
and compartmentalized within the cell [136]. Control of energy
production transfer and utilization by phosphotransfer kinases allows
servoing of mitochondria to excitation–contraction coupling.6.2. Energy phosphotransfer in heart failure
The group of J. Ingwall in Boston has been pioneer in demonstrat-
ing alterations in the creatine kinase system in hypertrophy and heart
failure [150]. Total creatine kinase decreases as much as 50% in heart
failure and positively correlates with ejection fraction [151]. Energy
reserve via the CK reaction was estimated by the product of total CK
activity and the content of total creatine in the heart, and decreased
energy reserve contributes to impaired contractile reserve in the
failing myocardium [1,128]. Indeed, it has been consistently observed
that both the cytosolic (MM-CK) and the mitochondrial (mi-CK)
isoforms of creatine kinase are decreased in experimental
[2,4,15,125,152] and human heart failure [2,4,15,125,152] (see [128]
for review). The decrease in mi-CK activity exceeds the decrease in
mitochondrial enzymes and is due to decreased protein content [15].
It has been shown that the abnormal myocardial high-energy
phosphate metabolism is related to the decreased in mi-CK, which
in turn is related to the severity of the hypertrophy [119]. Drop of mi-
CK pre-exists in severe hypertrophy and has been considered as a
hallmark of the transition to failure.
31P NMR spectroscopy also allows performing enzymology of CK
by using magnetization transfer of the phosphate moiety as a tracer of
energetic ﬂuxes. Alterations of the averaged CK ﬂux have been early
demonstrated in cardiac pathologies (for recent reviews see [4,128]).
In severe hypertrophy, CK ﬂuxes are decreased by 30 to 50%
[118,119,153]. In parallel, myokinase system, which normally con-
tributes to a lower extent to ATP supply, is signiﬁcantly increased as
revealed by 18O experiments as a compensatory mechanism [143].
The decrease in CK ﬂux is even more pronounced in heart failure as
described both in animal models [154] and recently in patients
[116,119,124,125,127,154,155]. The transition between severe hy-
pertrophy and heart failure actually results in a strong CK ﬂux
decrease, with no additional change in metabolite level, most
probably reﬂecting the decrease in CK activity [124]. Thus, the
decrease of CK ﬂux, rather than the level of hypertrophy, is an
indicator of heart failure.
It should be kept in mind however, that global approaches of
cellular ﬂuxes in NMR do not allow to discriminate ﬂuxes of the
different CK isoforms nor it takes into account the compartmentation
of energy ﬂuxes [148,149,156]. Although quantiﬁcation of 31P NMR
unidirectional ﬂuxes of localized CKs [144,146] have not been
performed for the failing heart, it can be hypothesized that the deﬁcit
in mi-CK will compromise the coupling between energy productionand utilization by the CK shuttle and that most of the energy transfer
will be insured directly by ATP.
7. Energy metabolism and cytoarchitecture
7.1. Mitochondria and direct energy transfer in normal heart
Energetic homeostasis of highly differentiated cells depends on
cellular architecture. Organization of the cytoskeleton may play a
major role in the regulation of energy exchange, since it is required for
positioning mitochondria and anchoring myoﬁbrils [157,158]. Cyto-
skeletal organization varies according to muscle type, and undergoes
remodeling in response to changing workload, environmental con-
straints and in pathology [157,159,160]. Indeed, mitochondrial
regulation by cytosolic ADP differs depending on muscle type [161],
probably due to the interaction between cytoskeleton and mitochon-
dria in oxidative tissues [37,162]. Changes in cell or organelle volume,
associated with physiological or pathological situations may also
affect the cytoarchitecture, energy exchange and contractile function
[163,164]. In addition, perturbation of cellular energetics can actually
lead to ultrastructural remodeling, for example due to CK gene
ablation [161,165], pharmacological depletion of creatine [166], or
hypoxia. Conversely, architectural perturbation can lead to energetic
alteration [167–169]. This suggests that cytoarchitecture may have a
signiﬁcant inﬂuence on energetic signaling.
Energetic microdomains, consisting on distinct ATP/ADP ratio, exist
between bound-CKs and ATPases but also at the interface of organelles
and are involved in energy regulation.Direct energy cross talks between
mitochondria and energy-consuming sites [165,170] are driven by
restriction diffusion for adenine nucleotides at the interface of the
organelles (Fig. 4) and are facilitated by the close apposition of sites that
produce and consume energy. Muscle mitochondria, for example,
appear to be clustered at sites of high ATP demand, because they are
organized into highly ordered, elongated bundles that wrap around the
myoﬁbrils and skirt the SR. This suggests that direct coupling of
organellesmay also bepossible, involving energy and signal channeling.
Recent studies have shown that indeed, ATP produced locally by
mitochondria could be directly channeled to ATPases and support
calcium uptake andmyoﬁbrillar contraction almost as effectively as ATP
supplied by CK/PCr, andmore effectively than cytosolic ATP, suggesting
a direct energetic crosstalk between these organelles through compart-
mentation of adenine nucleotides [165]. Direct energy channeling and
CK-supported energy supply seem to work on a competitive basis.
Assuming a one-to-one ATP production per creatine and an ADP/O ratio
of b3, it was estimated that more than 64% of the ATP consumed by
ATPases is directly channeled by the CK reaction and that direct
channeling with mitochondria accounts for less that 36%, showing the
greater efﬁciency of compartmentalized creatine kinase in basal
conditions [165]. Moreover, the two systems can compensate for each
other, indicating partial redundancy in the local ATP/ADP-controlling
systemsof cardiacmuscle. This is evident inmice lacking creatine kinase
were cardiac function can be rescued by direct energy channeling [165],
and direct support for the SR ATPase by glycolysis in heart muscle [171]
accompanied by intense cellular remodeling. However, it might be
anticipated that although these systems may appear redundant at rest
or duringmoderate workload in the heart, it is highly probable that at a
higher energy demand, they would have to be additively recruited and
their relative contributionmay bemodulated. In addition to controlling
the local adenine nucleotide pool, the CK system, as opposed to direct
energy cross-talk, can rapidly spread the information and harmoniously
equilibrate the energetic state throughout the cell because of the
presence of soluble CKs.
Further evidence for direct channeling of adenine nucleotides was
provided by V. Saks and his collaborators [20,172], who showed that
diffusion of ADP produced by cellular ATPases was restricted, and that
it was preferentially channeled to mitochondria instead of being
Fig. 4. Local bioenergetic alterations in heart failure. In normal heart, the ATP/ADP ratio at the vicinity of ATPases is ﬁnely controlled by bound phosphotransfer kinases (myokinase,
MK and creatine kinase, CK), glycolytic complexes, and mitochondria in close contact with other organelles. In the failing heart, mitochondrial content is decreased as well as the
amount of MK and CK. Moreover, disruption of the cell architecture weakens the direct nucleotide channeling between mitochondria and other organelles. This results in decreased
ATP/ADP ratio, loss of microdomains, and kinetic and thermodynamic decrease in ATPase efﬁciency.
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ADP increases the efﬁciency of interaction between mitochondria,
myoﬁbrils, the SR and probably other energy-consuming systems.
This organization into intracellular energetic units is probably
determined by the cytoskeleton, which governs the distribution of
mitochondria within muscle cells. Indeed, perturbation of the cardiac
cytoskeleton by desmin gene ablation affects mitochondrial localiza-
tion and regulation [157,170].
All these data show that maintaining metabolic homeostasis
despite ﬂuctuating energy demand is an important prerequisite for
contractile efﬁciency. This emphasizes the fact that cell architecture
and metabolic networks are interrelated to build integrated phospho-
transfer systems that improve cellular economy to tightly match
cellular functions, and that alterations in this ﬁne regulation can
compromise cardiac function.
This may be especially important in the pathogenesis of muscle
disease such as heart failure, in which energy handling is impaired
concomitant with remodeling of mitochondrial morphology and the
cytoskeleton.
7.2. Mitochondria and direct energy transfer in heart failure
HF is characterized by impairment in intracellular organization
[173,174]. Alterations of microtubules or intermediate ﬁlamentEnergy production
Energy transfert
Energy Utilization
Energetic efficiency
Production
Metabolic
therapy??
Fig. 5. Energetic unbalance in heart failure. Heart failure is characterized by an increase in e
heart failure tend to decrease energy demand. Future therapies of heart failure may tend toprotein expression may contribute to the functional defect [64,175–
177]. Cytoskeletal organization plays a role in energy transfer
[162,169], as it is required for positioningmitochondria and anchoring
myoﬁbrils [157] and disruption of the cytoskeleton induces speciﬁc
alteration of mitochondria–SR interaction and calcium homeostasis
[170] as well as local loss of mitochondria [178]. However, it is
important to know if locally, in the vicinity of ATPases, this decrease
and these alterations have functional repercussions. For example, a
decrease in calcium storage capacity of the SR directly linked to a local
decrease in ATP/ADP ratio could be observed [82]. This was not due to
a failure of calcium pump, because maximal activation of glycolysis
was sufﬁcient to restore a normal SR loading. This conﬁrms that
energy supply is a limiting factor for SR function in HF, and that
glycolysis plays amore important role in HF in supporting SR function,
to compensate for the impairment of CK and mitochondria. A similar
alteration of energy transfer could be observed in myoﬁlaments.
Getting energy speciﬁcally to where it is required is thus an additional
energetic problem in heart failure [179].
In the healthy heart, the two main energy-supplying systems (CK
and direct mitochondrial energy channeling) can partially compen-
sate each other, which is essential for having energetic reserve when
energy demand of workload is increased. However, in HF, this is not
anymore the case [82]. The decrease in mitochondrial content, in mi-
andMM-CK activities, and the disorganization of the cytoarchitecture,Contractile demand
Calcium demand
Contractile efficiency 
Demand
Diuretics
ACEi
β-blockers
nergy demand and a decrease in energy production and transfer. Current treatments of
improve energy metabolism to re-equilibrate the energetic balance.
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energy utilization participating in the failure of the cardiac pump.
Finally, HF is associated with morphologic abnormalities of cardiac
mitochondria including increased number, reduced organelle size and
compromised structural integrity, suggesting fragmentation of the
mitochondrial network [65,99,173]. Mitochondrial injury identiﬁed as
matrix depletion, membrane disruption and scrolling, positively
correlates with indexes of heart failure severity like plasma
norepinephrine, left ventricle (LV) end-diastolic pressure and ejection
fraction [173]. An emerging hypothesis is that the mechanisms which
control mitochondrial shape, and in particular mitochondrial dynam-
ics, could play a role in heart disease [80,180]. In HF, a decrease in
OPA1, a dynamin involved in the fusion of inner mitochondrial
membrane, has been implicated in the regulation of energy ﬂuxes and
size and shape of mitochondria all factors that can be critical for
optimum energy transfer [80]. However, it is not clear so far whether
decreases in expression of proteins involved in fusion and ﬁssion
processes are per se responsible for energetic disorders, or if there are
just a consequence of mitochondrial mass decrease. Further experi-
ments are needed to demonstrate the link between mitochondrial
dynamics and energetic, especially in adult cardiomyocytes where
only a few studies have been performed.
8. Towards a metabolic therapy of heart failure
Heart failure is still associatedwith an annualmortality rate of 10%,
urging to develop new therapeutic strategies. Because heart failure
becomes more common with increasing age, the number of affected
individuals is rising with the rapidly ageing population. New
treatments that target disease mechanisms at the cellular and
whole-organ level are needed to halt and reverse the devastating
consequences of this disease. Although the exact mechanisms are not
completely understood, alterations in energy metabolism point at a
more important role for energy metabolism in the pathophysiology of
heart failure than previously thought. Physiological and biochemical
studies, non invasive NMR spectroscopy of energy-rich phosphates,
large scale studies in humans and more recently proteomic and
transcriptomic studies have reactivated the concept of energy
starvation of the failing myocardium as a major component of the
pathophysiology of HF. It leads to an energetic unbalance between the
work the heart has to perform and the production, transfer and
utilization of energy (Fig. 5) that argue in favor of a metabolic therapy
of heart failure [7,67,181–183].
Interestingly, part of the beneﬁcial effects of the current treat-
ments of heart failure can be explained by energy sparing effects. By
decreasing circulating blood volume, diuretics decrease volume
overload and thus energy demand. By decreasing peripheral resis-
tance and RAAS activation, ACE inhibitors decrease the load against
which the heart has to perform, thus also reducing energy demand
and hormonal overdrive. A beneﬁcial effect of ACEi therapies on
oxidative capacity has been observed and proved to be effective in
skeletal muscle but incomplete in cardiac muscle [57,62,63]. Beta-
blockers that reduce adrenergic stimulation of the heart and cardiac
frequency also result in energy sparing effects. Finally, cardiac
resynchronization therapy (CRT) improves morbidity and mortality
of CHF patients with ventricular dyssynchrony and potently affects
bothmitochondrial protein and function in associationwith improved
cardiac function and efﬁciency [184–186]. Nevertheless, despite
signiﬁcant progresses in the last twenty years, heart failure is still
associated with high morbi-mortality rate. The search for additional
treatments is a burning issue. Metabolic therapy of heart failure is
thus an original concept that has recently being proposed as a new
ﬁeld of research. From this perspective therapies aimed at preserving
mitochondrial function and optimizing substrate metabolism appear
to be worthwhile pursuits in the effort to stop the progression of heart
failure [181]. Interventions aimed at counteracting the substrateswitch has received recent attention but the success of such
hypothesis depends on whether the shift from fatty acid towards
glucose utilization should be considered beneﬁcial or detrimental, a
question that is still incompletely solved [8] and will strictly depend
on the mitochondrial capacity to metabolize these substrates [187].
Because PGC-1α is the master regulator of energy metabolism,
improvement of the cardiac energetic status by restoring PGC-1α
transcriptional activity has promises as a newapproach in the treatment
of heart failure. Improving mitochondrial biogenesis by up-regulating
PGC-1α is a strategy largely atwork inmetabolic diseases likemetabolic
syndrome, obesity and diabetes. Indeed, PGC-1α being upstream of all
the regulation of energy metabolism, targeting it represents an original
approach allowing a harmonious improvement of energy metabolism
[67,188]. Normalizing PGC-1α content in the failing heart may improve
substrate utilization, oxidative capacity, antioxidant defenses and
potentially mitochondrial dynamic and energy transfer by increasing
mi-CK expression. The combination of energy metabolism remodeling
and load improvement, could synergistically rescue the failing heart.
However, PGC-1α seems to be regulated in a cardiac speciﬁc manner
[67] and more work is needed to understand its role and regulation in
thenormal and failingheart. BecauseHF is also ametabolic disease, such
a strategy could be beneﬁcial in this pathology.References
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